Quarterly report · Q2
2934.TEDINET S100PYFW
Period2022-06-01 → 2022-11-30
Filed2023-01-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥9.1bn | 2022-06-01 → 2022-11-30 | Cons. | Net sales |
| Revenue | ¥11.9bn | 2021-06-01 → 2022-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.9bn | 2021-06-01 → 2021-11-30 | Cons. | Net sales |
| Operating income | −¥368m | 2022-06-01 → 2022-11-30 | Cons. | Operating income |
| Operating income | ¥264m | 2021-06-01 → 2021-11-30 | Cons. | Operating income |
| Ordinary income | −¥382m | 2022-06-01 → 2022-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥713m | 2021-06-01 → 2022-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥238m | 2021-06-01 → 2021-11-30 | Cons. | Ordinary income |
| Profit before tax | −¥382m | 2022-06-01 → 2022-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥238m | 2021-06-01 → 2021-11-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥349m | 2022-06-01 → 2022-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥401m | 2021-06-01 → 2022-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥156m | 2021-06-01 → 2021-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥308m | 2022-06-01 → 2022-11-30 | Cons. | Profit loss |
| Net income | ¥156m | 2021-06-01 → 2021-11-30 | Cons. | Profit loss |
| Total assets | ¥7.8bn | at 2022-11-30 | Cons. | Assets |
| Total assets | ¥6.1bn | at 2022-05-31 | Cons. | Assets |
| Total assets | ¥5.5bn | at 2021-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥3.6bn | at 2022-11-30 | Cons. | Liabilities |
| Total liabilities | ¥1.9bn | at 2022-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥4.2bn | at 2022-11-30 | Cons. | Net assets |
| Net assets / equity | ¥4.2bn | at 2022-05-31 | Cons. | Net assets |
| Net assets / equity | ¥4.3bn | at 2021-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.9bn | at 2022-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.0bn | at 2022-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.8bn | at 2022-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2022-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.1bn | at 2021-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2021-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥594m | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥367m | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥288m | 2021-06-01 → 2021-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥800m | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥860m | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥77m | 2021-06-01 → 2021-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.3bn | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.6bn | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.8bn | 2021-06-01 → 2021-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-76.45 | 2022-06-01 → 2022-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-47.82 | 2022-09-01 → 2022-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.64 | 2021-06-01 → 2022-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥36.31 | 2021-06-01 → 2021-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥19.01 | 2021-09-01 → 2021-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥86.68 | 2021-06-01 → 2022-05-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥34.33 | 2021-06-01 → 2021-11-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 50.9% | at 2022-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.2% | at 2022-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.9% | at 2021-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 31
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-06-01 → 2022-11-30 | −¥84m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-06-01 → 2022-11-30 | −¥84m |
| Reconciling Itemsreconciling | segment profit | 2022-06-01 → 2022-11-30 | −¥277m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥3.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥2.9bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥84m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥55m |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥266m |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥4.2bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥4.2bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥181,000 |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | segment profit | 2022-06-01 → 2022-11-30 | −¥412m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-06-01 → 2022-11-30 | ¥9.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-06-01 → 2022-11-30 | ¥9.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥84m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-06-01 → 2022-11-30 | −¥91m |
| Reconciling Itemsreconciling | segment profit | 2021-06-01 → 2021-11-30 | −¥195m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue | 2021-06-01 → 2021-11-30 | ¥552m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue external | 2021-06-01 → 2021-11-30 | ¥552m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | segment profit | 2021-06-01 → 2021-11-30 | ¥64m |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue | 2021-06-01 → 2021-11-30 | ¥1.9bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue external | 2021-06-01 → 2021-11-30 | ¥1.9bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | segment profit | 2021-06-01 → 2021-11-30 | ¥391m |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue | 2021-06-01 → 2021-11-30 | ¥1.4bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue external | 2021-06-01 → 2021-11-30 | ¥1.4bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | segment profit | 2021-06-01 → 2021-11-30 | ¥5m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-06-01 → 2021-11-30 | ¥3.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-06-01 → 2021-11-30 | ¥3.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-06-01 → 2021-11-30 | ¥459m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 489
| Item | Context | Value | Unit |
|---|---|---|---|
| Interest expenses ope cf | Prior1YTDDuration | 179000 | JPY |
| Interest expenses ope cf | CurrentYTDDuration | 5095000 | JPY |
| Stock issuance cost ope cf | Prior1YTDDuration | 25778000 | JPY |
| Stock issuance cost ope cf | CurrentYTDDuration | － | JPY |
| Issuance cost of subscription rights to shares ope cf | Prior1YTDDuration | － | JPY |
| Issuance cost of subscription rights to shares ope cf | CurrentYTDDuration | 9384000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YTDDuration | -77597000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYTDDuration | 98582000 | JPY |
| Decrease increase in inventories ope cf | Prior1YTDDuration | 113897000 | JPY |
| Decrease increase in inventories ope cf | CurrentYTDDuration | -120331000 | JPY |
| Decrease increase in prepaid expenses ope cf | Prior1YTDDuration | -121113000 | JPY |
| Decrease increase in prepaid expenses ope cf | CurrentYTDDuration | -38303000 | JPY |
| Decrease increase in consumption taxes refund recievable ope cf | Prior1YTDDuration | － | JPY |
| Decrease increase in consumption taxes refund recievable ope cf | CurrentYTDDuration | -31198000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YTDDuration | 90876000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYTDDuration | -152733000 | JPY |
| Increase decrease in accounts payable other ope cf | Prior1YTDDuration | -311355000 | JPY |
| Increase decrease in accounts payable other ope cf | CurrentYTDDuration | 164017000 | JPY |
| Increase decrease in accrued expenses ope cf | Prior1YTDDuration | -17552000 | JPY |
| Increase decrease in accrued expenses ope cf | CurrentYTDDuration | -6808000 | JPY |
| Increase decrease in accrued consumption taxes ope cf | Prior1YTDDuration | 4275000 | JPY |
| Increase decrease in accrued consumption taxes ope cf | CurrentYTDDuration | -45092000 | JPY |
| Other net ope cf | Prior1YTDDuration | -990000 | JPY |
| Other net ope cf | CurrentYTDDuration | -6021000 | JPY |
| Subtotal ope cf | Prior1YTDDuration | -49249000 | JPY |
| Subtotal ope cf | CurrentYTDDuration | -357446000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1YTDDuration | 8000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYTDDuration | 107000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -144000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -5075000 | JPY |
| Income taxes paid ope cf | Prior1YTDDuration | -238784000 | JPY |
| Income taxes paid ope cf | CurrentYTDDuration | -231340000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | -288169000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | -593755000 | JPY |
| Payments into time deposits inv cf | Prior1YTDDuration | － | JPY |
| Payments into time deposits inv cf | CurrentYTDDuration | -75000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -5400000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -63842000 | JPY |
| Purchase of intangible assets inv cf | Prior1YTDDuration | -149000 | JPY |
| Purchase of intangible assets inv cf | CurrentYTDDuration | － | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | Prior1YTDDuration | -71552000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | CurrentYTDDuration | -576977000 | JPY |
| Purchase of investment securities inv cf | Prior1YTDDuration | － | JPY |
| Purchase of investment securities inv cf | CurrentYTDDuration | -40002000 | JPY |
| Payments of loans receivable inv cf | Prior1YTDDuration | － | JPY |
| Payments of loans receivable inv cf | CurrentYTDDuration | -32000000 | JPY |
| Other net inv cf | Prior1YTDDuration | － | JPY |
| Other net inv cf | CurrentYTDDuration | -12504000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -77102000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -800326000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |